Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc (NQ: VRCA )

12.69 USD -1.00 (-7.30%)
Official Closing Price Updated: 7:57 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Verrica Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
From GlobeNewswire News Releases
Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
From GlobeNewswire News Releases
Verrica Announces Pricing of Public Offering of Common Stock
From GlobeNewswire News Releases
Verrica Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan
Torii to make upfront payment of $11.5 million to Verrica in addition to other potential milestone payments of up to $58 million and, if marketed in Japan, tiered transfer price payments as a... 
From GlobeNewswire News Releases
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
From GlobeNewswire News Releases
Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Confer
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum
- Verrica reaffirms expectation to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 - 
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference
From GlobeNewswire News Releases
Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)
From GlobeNewswire News Releases
Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results
From GlobeNewswire News Releases
Gore Range Capital Bolsters Advisory Board for Skin Health Investments
Gore Range Capital adds world-class advisory board members to new skin health venture capital fund 
From Business Wire News Releases
JAMA Dermatology Publishes Results from Verrica’s Two Pivotal Phase III CAMP (Cantharidin Application in Molluscum Patients) Trials
From GlobeNewswire News Releases
Novan Inc. and Verrica Pharmaceuticals Participate in Virtual Panel to Discuss Developing Treatments for Molluscum Contagiosum on SNN Network
From ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA
From PR Newswire
VRCA Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA)... 
From PR Newswire
DEADLINE TODAY: The Schall Law Firm Announces It Is Investigating Claims Against Verrica Pharmaceuticals Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Verrica Pharmaceuticals Inc. 
From Business Wire News Releases
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Verrica... 
From Business Wire News Releases
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)
Law Offices of Howard G. Smith reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Verrica... 
From PR Newswire
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From GlobeNewswire News Releases
VRCA Class Action Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020
From GlobeNewswire News Releases
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)
Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Verrica Pharmaceuticals Inc.... 
From PR Newswire
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment Conference
From GlobeNewswire News Releases
Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Verrica Pharmaceuticals Inc. To Contact The Firm
From NewMediaWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA
Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such investors are advised to contact Robert S. Willoughby at... 
From PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.